YiPSCELL is Korea’s first start-up based on induced pluripotent stem cell technology.
We produce stem cell lines derived from normal humans and patient
using the next generation stem cell technology called “induced pluripotent stem cell”
and produce disease modeling platform services that can replace animal experiments.
We are a biotechnology company that establishes various diagnostic and treatment pipelines,
such as developing stem cell-based treatments.
Ceo Message
YiPSCELL’s executives and employees consider
“Seek for the Sick”,
the company’s core philosophy, as the most important value.
Greetings!
I'm JiHyeon Ju, CEO of YiPSCELL
YiPSCELL is a biotech company that uses induced pluripotent stem cells to produce normal and diseased cell lines,
provide platform services for disease modeling, and develop stem cell-based therapeutics.
“Seek for the sick”
We are committed to research, development, and application processes to diagnose and treat patients
with incurable diseases that cannot be resolved with modern medicine.
“From Therapy to Recovery”
We have established a strategy to focus on induced pluripotent stem cells among various stem cells.
Induced pluripotent stem cells have great potential
because it is easy to acquired cells and has a wide range of differentiation capabilities.
We will develop stem cell therapies that aim regeneration and functional recovery
of ageing organs so as to provide promising treatments in this era of ultra-aging society.
“Without passion, noting is gained”
The process of developing new treatments requires continuous eagerness and enthusiasm.
With this passion, YiPSCELL aims to contribute to the society by conducting R&D on induced pluripotent stem cells
from therapeutic approaches for patients with incurable disease.
We would be grateful if you would follow us with great interest.
CEO JiHyeon Ju
YiPSCELL Co,. Ltd.
History
YiPSCELL conducts clinical immunology & stem cell research
and aims to proceed induced pluripotent stem cell research and develop therapeutics based on our research.
2024
08
Winner of the “IR52 Jang Young-Sil Award” for technological innovation
08
Acquisition of MFDS “Human Cell Management Business” license
08
MIUChon receives IND (Clinical Trial Planning) approval from the MFDS
2023
12
recipient the 2023 Presidential Award for Entrepreneurship in Biohealthcare
11
recipient the 2023 Minister of Trade, Industry and Energy's Recognition for Job Creation Award
09
Signed MOU with 'Acrocell Biosciences'
08
Signed MOU with 'Surginex'
07
Signed MOU with 'One Heart Blood Center'
05
Signed MOU with ‘AJOU University Institute of Advanced Medical Studies’
05
Signed MOU with 'Daewoong Pharmaceutical '
05
Selected as one of the “Small Business Administration Super Gap Startups 1000+”
04
Selected as a follow-up support project for BIG3 Startup Package (fostering new industry startups)
04
Selected for the Health Industry Technology Valuation Project
04
Acquisition of GMP cell processing facility license
03
Personalized iPSC Bank Start
02
Korea's first CAR-T therapy approved for systemic lupus erythematosus patients in South Korea
01
Signed MOU with 'EDGENE'
2022
12
Apply for MIUChon Patent
12
Signed MOU with 'curocell'
12
Signed MOU with 'Paean Biotechnology'
12
Raised 3 billion won in bridge funding
11
Signed MOU with 'ToolGen Bio'
11
Winner of the Ministerial Award for Technology Commercialization Achievement from the Ministry of Health and Welfare
11
Raised 10 billion won in bridge funding
11
Selected as an outstanding company for technological innovation based on industry-academia cooperation
09
Selected as a recipient of the 2022 Technology Protection Leading Company Development Project
06
Extended Moving to 'Omnibus Park'
01
Selected as a National 1000 Innovative Company by the Ministry of SMEs and Startups
01
Apply for a Cell Processing Facility (GMP) License
01
Signed a license agreement with CiRA in Japan
01
Signed MOU with 'MDimune'
2021
12
Awarded “Excellence in LMO Security Management for Pilot Research Facilities” by the Minister of Science, ICT and Future Planning 2021
09
Signed MOU with 'Jasang Bio'
07
Production of clinical grade induced pluripotent stem cell lines
06
Certification as Venture (Start-up) Company
05
Investments Worth 12 Billion Korean Won Secured in Series A Round (INTERVEST, AJU IB, PremierPartners, HB INVESTMENT)
02
YiPSCELL Laboratory Receives LMO Certification
2020
11
3rd Floor GCLP-Level Laboratory Opens
11
Won “Minister Citation of Ministry of Gender Equality and Family” at K-Startup Challenge 2020
Commercialization support project of Innovation Growth (Seoul Business Agency)
09
Commercialization support project of BIG 3 R&D (Ministry of SMEs and Startups)
05
Start-up leap forward package support project (KISED)
05
Commercialization support project of BIG 3 innovation field start-up package (KIAT)
04
Headquarter expansion and relocation (47-3 Banpo-daero 39-gil, Seocho-gu, Seoul)
2019
12
Patent transfer contract and technology transfer between The Catholic University Industry-Academic Cooperation Foundation and CiSTEM
11
Catholic Master Cell, the first clinical trial for osteoarthritis patients
10
Won “Best Award” at 2019 Anti-Aging Health Startup Fair hosted by Korea Economic Daily
10
Awarded for contributing to commercialization of health and medical technology Awarded by KHIDI
09
Initial start-up package business order
05
Signed a joint development contract with T&R Biofab and CiSTEM for treatment of rare immune diseases
03
Innovative startup member business of KHIDI
2018
12
Patent for systemic sclerosis disease model and its use (application number 10-2019-0177114, PCT/KR2019/018654)
06
Patent on a method for producing a pellet of chondrocytes from human induced pluripotent stem cells and its use (application number 10-2018-0072875)
01
Patent registration of chondrocytes induced differentiation using separation by cell size through centrifugation (Registration No. 10-2014020)
2017
12
Patent for a method of manufacturing a composition for differentiation of chondrocytes using human pluripotent cells derived from umbilical cord blood mononuclear cells of HLA homozygous
(Registration No.: 10-2030906)
02
Founded CiSTEM Co., Ltd. located in Catholic University, 222 Banpo-daero, Seocho-gu, Seoul
2016
03
Catholic iPSC Research Center (CiRC) Established Induced Pluripotent Stem Cell Application Research Center under the Catholic University of Korea
2010
03
Established CiSTEM laboratory
Brand Story
YiPSCELL’s visual identity was inspired by three things.
The Rod of Asclepius God of medicine, to express YiPSCELL’s ideology devoted to human health
Helix structure of a DNA to symbolize YiPSCELL’s efforts to because the leading company in the field of biology science
As we prepare a signpost to indicate the future of YiPSCELL for development and delve into unlimited and infinite
The completed identity as whole resembles an alive branch that represents blessing
and creates an association with the company name similarly to the Korean “leaf”.
Each quadrilateral that makes up the identity symbolizes core values that YiPSCELL pursues :
Compassion, Supremacy, and Contribution.
